Join
Live feed
·
PRReleasevia Quantisnow
SCYNEXIS Inc. logo

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022

ByQuantisnow·Wall Street's wire, on your screen.
SCYX· SCYNEXIS Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SCYX (SCYNEXIS Inc.) and more on Quantisnow.